ArticleClinical rheumatology2022
Multisystem inflammatory syndrome in children: clinical presentation, management, and short- and long-term outcomes.
Article in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Post-MIS-C cardiovascular outcomes: a systematic review.European journal of pediatrics · 2026Pooled it
- Prevalence and risk factor for long COVID in children and adolescents: A meta-analysis and systematic review.Journal of infection and public health · 2023Pooled it
- Low ICU Admission and Excellent Outcomes in MIS-C: A Swedish Study From an Open Society.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- MIS-C: Diagnosis, Management, and Outcomes.Open forum infectious diseases · 2026Review
- Incidence, Clinical Profile, and Cardiac Manifestations of MIS-C in Children in Kuwait.Diagnostics (Basel, Switzerland) · 2025Article
- Two-year follow-up on multisystem inflammatory syndrome in children (MIS-c): findings from a tertiary paediatric hospital in Latvia.European journal of pediatrics · 2025Article
- Comparison of methylprednisolone alone versus intravenous immunoglobulin plus methylprednisolone for multisystem inflammatory syndrome in children (MIS-C).BMJ paediatrics open · 2025Article
- Severity predictors for multisystemic inflammatory syndrome in children after SARS-CoV-2 infection in Vietnam.Scientific reports · 2024Article
- Long-term outcomes and immune profiling in children with multisystem inflammatory syndrome (MIS-C).Acta bio-medica : Atenei Parmensis · 2023Article
- Cardiac Outcome of Children With SARS-CoV-2 Related Multisystem Inflammatory Syndrome.Indian pediatrics · 2023Review
- Cardiac MRI with late gadolinium enhancement shows cardiac involvement 3-6 months after severe acute COVID-19 similar to or worse than PIMS.Frontiers in cardiovascular medicine · 2023Article
- Risk factors for health impairments in children after hospitalization for acute COVID-19 or MIS-C.Frontiers in pediatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn this study, it was aimed to evaluate the demographic, clinical and laboratory characteristics of MIS-C patients in our hospital, to share our treatment approach, and to assess the outcomes of short- and long-term follow-up.
methodsMIS-C patients who were admitted and treated in our hospital between July 2020 and July 2021 were evaluated. Demographic, clinical, laboratory, and follow-up data were collected from patient records retrospectively.
resultsA total of 123 patients with MIS-C (median age, 9.6 years) were included the study. Nineteen (15.4%) were mild, 56 (45.6%) were moderate, and 48 (39%) were severe MIS-C. High CRP, ferritin, pro-BNP, troponin, IL-6, and D-dimer values were found in proportion to the severity of the disease (p < 0.001, p < 0.001, p < 0.001, p < 0.001, p = 0.005, p < 0.001), respectively. Two (1.6%) patients died. The mean follow-up period was 7.8 months. Valve failure, left ventricular dysfunction/hypertrophy, coronary involvement, and pericardial effusion were the most common cardiac pathologies in the short- and long-term follow-up of the patients. In the long-term follow-up, the most common reasons for admission to the hospital were recurrent abdominal pain (14.2%), cardiac findings (14.2%), pulmonary symptoms (8%), fever (7.1%), neuropsychiatric findings (6.2%) and hypertension (3.5%). Neuropsychiatric abnormalities were observed significantly more common in severe MIS-C patients at follow-up (p = 0.016). In the follow-up, 6.2% of the patients required recurrent hospitalization.
conclusionMIS-C is a serious and life-threatening disease, according to short-term outcomes. In addition to the cardiac findings of patients with MIS-C, long-term outcomes such as neuropsychiatric findings, persistent gastrointestinal symptoms, fever and pulmonary symptoms should be monitored. Key Points • In MIS-C patients, attention should be paid not only to cardiac findings, but also to symptoms related to other systems. • Patients should be followed up in terms of neuropsychiatric findings, persistent gastrointestinal symptoms, fever and pulmonary symptoms that may occur during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.